Adrenomed is a clinical-stage biopharmaceutical company based in Berlin, Germany. The company’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Adrenomed’s unique treatment approach combines a therapeutic antibody with a specific diagnostic that uses Adrenomedullin as the biomarker to identify patients.
Targeting Vasoprotective Peptide Adrenomedullin
Adrenomed’s lead product candidate is Adrecizumab, a clinical-stage, first-in-class monoclonal antibody that targets the vasoprotective peptide Adrenomedullin. Adrenomedullin is an essential regulator of vascular integrity, and Adrecizumab aims to treat life-threatening conditions associated with increased vascular leakage, congestion, and shock. The most important target indications are sepsis and septic shock as well as acute heart failure.
Combining Therapeutic Antibody with Specific Diagnostic
Adrenomed’s unique treatment approach combines a therapeutic antibody with a specific diagnostic that uses Adrenomedullin as the biomarker to identify patients. This combination approach allows for more precise and targeted treatment of patients, increasing the likelihood of positive outcomes.
Strong IP Position
Adrenomed’s business is effectively secured by a strong IP position with granted patents in all major markets. This gives the company a competitive advantage in the biopharmaceutical industry and ensures that their innovative treatments are protected.
Saving Lives
Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. The company’s focus on sepsis and septic shock as well as acute heart failure addresses some of the most pressing medical challenges of our time. By combining a therapeutic antibody with a specific diagnostic, Adrenomed is at the forefront of innovative biopharmaceutical treatments that could save countless lives.
Conclusion
Adrenomed is a clinical-stage biopharmaceutical company based in Berlin, Germany, that is focused on rescuing vascular integrity in order to save the lives of critically ill patients with limited treatment options. Adrenomed’s lead product candidate, Adrecizumab, targets the vasoprotective peptide Adrenomedullin and combines a therapeutic antibody with a specific diagnostic that uses Adrenomedullin as the biomarker to identify patients. With a strong IP position and a focus on some of the most pressing medical challenges of our time, Adrenomed is at the forefront of innovative biopharmaceutical treatments that could save countless lives.
Website: http://www.adrenomed.com
Twitter: https://twitter.com/adrenomed
LinkedIn: https://www.linkedin.com/company/adrenomed-ag
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!
